Previous 10 | Next 10 |
Exelixis ([[EXEL]] +1.6%) exercises its option for Aurigene's CDK7 inhibitor, now known as XL102, and submits an Investigational New Drug Application to the U.S. Food and Drug Administration to evaluate XL102 alone or in combination therapy for treatment of inoperable locally advanced or meta...
Dosing is underway in a Phase 3 clinical trial, PRESECO, evaluating Appili Therapeutics' (APLIF) Avigen tablets (favipiravir) for the treatment of COVID-19 patients with mild-to-moderate symptoms. The goal is to alleviate the symptoms and prevent disease progression.Enrollment target is ~826 ...
Dr. Reddy's Laboratories (RDY) announces the start of an adaptive Phase 2/3 clinical trial in India evaluating Russia's Sputnik V COVID-19 vaccine. The study will be conducted by JSS Medical Research.An adaptive study allows for modifications to the trial and/or statistical models while the s...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), and Russian Direct Investment Fund (RDIF) announced today that they have commenced adaptive phase 2/3 clinical trials for Sputnik V vaccine in India after receiving the necessary clearance from the Central Drug...
Dr Reddy's Laboratories (RDY) inked a pact with Glenmark Pharmaceuticals to acquire brands Momat Rino (for Russia, Kazakhstan and Uzbekistan), Momat Rino Advance (for Russia), Momat A (for Kazakhstan and Uzbekistan), Glenspray and Glenspray Active (for Ukraine), along-with rights to the trade...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced that it has entered into a definitive agreement with Glenmark Pharmaceuticals Ltd. to acquire, subject to c...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL), Multiple-Dose Vials a therap...
Pfizer and BioNTech's announcement that, based on preliminary data, their COVID-19 vaccine is 90% effective and an emergency use authorization ((EUA)) is only weeks away has led to downward pressure on some of the second tier developers. If all goes according to plan, deployment could start b...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced a preclinical data presentation for E7777 (denileukin diftitox), its engineered IL-2-diphtheria toxin fusio...
Dr. Reddy’s Laboratories (RDY) joins forces with Biotechnology Industry Research Assistance Council ((BIRAC)), Department of Biotechnology ((DBT)), Government of India, for advisory support on clinical trials of Sputnik V vaccine in India. The partnership will allow Dr. Reddy’s ...
News, Short Squeeze, Breakout and More Instantly...
Dr. Reddy's Laboratories Ltd Company Name:
RDY Stock Symbol:
NYSE Market:
Dr. Reddy's Laboratories Ltd Website:
2024-07-04 03:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Portfolio to be acquired consists of global NRT brand Nicotinell and its local market-leading brand names Nicabate, Habitrol and Thrive in markets outside of the United States Acquisition seen as ideal anchor to continue to build the company’s global consumer healthcare OTC busines...
Aurigene Pharmaceutical Services Limited (“Aurigene”), a Dr. Reddy’s Laboratories Limited company, inaugurated its biologics facility spread across 70,000 sq.ft. in Genome Valley, a bio cluster, located in Hyderabad, India. The facility is designed to serve customers with pro...